The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
-
Alabama Kidney Research, Alabaster, Alabama, United States, 35007
EmVenio Research, Birmingham, Alabama, United States, 35210
Cardiology, P.C., Birmingham, Alabama, United States, 35211
Nephrology Associates, Fairhope, Alabama, United States, 36532
Heart Center Research LLC, Huntsville, Alabama, United States, 35801
Nephrology Consultants, LLC, Huntsville, Alabama, United States, 35805
Renal Associates of Alabama, LLC, Montgomery, Alabama, United States, 36117
EmVenio Research, Vestavia Hills, Alabama, United States, 35216
AKDHC Medical Research Service LLC - Banner Desert Office, Mesa, Arizona, United States, 85016
AKDHC Medical Research Service LLC, Phoenix, Arizona, United States, 85016
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
10 Years to 65 Years
ALL
No
Vertex Pharmaceuticals Incorporated,
2026-06-30